Autoplaque vs LVivo IQS
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a detailed, quantitative analysis of coronary artery plaque and luminal stenosis from CT angiography images. This tool is ideal for precisely assessing atherosclerotic plaque burden and severity to inform heart attack risk prediction and guide treatment strategies, offering automated segmentation and comprehensive views for in-depth evaluation of coronary anatomy and pathology.
View Autoplaque →Choose LVivo IQS if…
Choose LVivo IQS if you require AI-powered automation for ultrasound image analysis, particularly for assessing cardiac function at the point of care or in a high-volume setting. This solution enhances diagnostic confidence and efficiency by providing real-time image quality feedback and automated evaluation of global and segmental left and right ventricular function, standardizing and streamlining ultrasound interpretations.
View LVivo IQS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | LVivo IQS |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | As an integrated part of an ultrasound and information technology (IT) system. |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
LVivo IQSLVivo IQS (Tool B) offers real-time image quality feedback directly on ultrasound devices, enhancing usability during image acquisition at the bedside within the clinical workflow. Autoplaque (Tool A) is a workstation-based post-processing application, requiring a separate step after image acquisition. The immediate, in-workflow assistance provided by LVivo IQS offers a more integrated and efficient user experience.
Clinical Value
AutoplaqueAutoplaque (Tool A) provides detailed, quantitative analysis of coronary plaque and luminal stenoses from CT angiography images, directly aiding in heart attack risk prediction and treatment guidance, supported by clinical validation. While LVivo IQS (Tool B) improves the quality and interpretability of cardiac ultrasound images in real-time, Autoplaque's focus on advanced plaque characterization for high-stakes risk prediction from CTA data offers a deeper and more specific clinical insight in a critical area of cardiology.
Pricing & Value
TieBoth Autoplaque (Tool A) and LVivo IQS (Tool B) lack transparent, publicly disclosed pricing for their core software products. Without specific pricing information for either tool, it is impossible to conduct a meaningful comparison of their respective value propositions or determine a winner in this dimension.
Enterprise Readiness
LVivo IQSLVivo IQS (Tool B) demonstrates stronger enterprise readiness with explicit HIPAA compliance, implied BAA, vendor-neutrality, and flexible deployment options including PACS systems/servers. Autoplaque (Tool A) is workstation-based and lacks specified HIPAA compliance or BAA information, which are crucial considerations for integration into large healthcare IT environments.
Innovation
LVivo IQSLVivo IQS (Tool B) provides real-time AI-powered feedback during ultrasound acquisition to ensure high-quality, interpretable images, which is a novel approach to improving diagnostic consistency and efficiency directly at the point of care. Autoplaque (Tool A) offers advanced, quantitative AI analysis of complex coronary plaque characteristics from CTA, which is highly specialized, but LVivo IQS's real-time, in-workflow quality feedback represents a more disruptive innovation for improving fundamental data acquisition quality.
Support & Docs
TieWhile Autoplaque's (Tool A) FDA documentation mentions the existence of a user manual, specific details on comprehensive support, training, or extensive documentation for either product are not readily available from the provided information or web searches. Therefore, without sufficient comparative data, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | LVivo IQS |
|---|---|---|
| Name | Autoplaque | LVivo IQS |
| Company | Cedars-Sinai Medical Center: AIM | DiA Imaging Analysis |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | DiA Imaging Analysis offers AI-powered ultrasound solutions, including LVivo IQS, to automate and enhance image analysis for improved diagnostic confidence and efficiency in cardiology and other fields. |
| Primary Imaging Modality | CT Angiography | Ultrasound |
| Key Feature 1 | AI-powered quantitative analysis of atherosclerotic plaque | AI-powered real-time image quality feedback (LVivo IQS) |
| Key Feature 2 | Detection and characterization of coronary artery plaque | Automated analysis of ultrasound images |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and LVivo IQS.
Frequently Asked Questions
More Comparisons
More matchups featuring Autoplaque or LVivo IQS
Backers
Who funded each tool's parent company.